6 signals · News / RSS
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Moderate stress signals detected across available public data.
Recursion Pharmaceuticals in the AI Drug Discovery space shows elevated workforce stress signals and moderate risk indicators, based on 3 signals across 1 source.
Signals for Recursion Pharmaceuticals were collected from 1 source. Aggregate signal sentiment appears broadly cautionary. The stress score stands at 65/100 with a risk score of 55/100. These findings are based on a limited number of signals and may not be fully representative.
What this means
Limited signals collected so far — this score may shift significantly as more data arrives.
AI-generated from public signals — may be incomplete.
Recursion Pharmaceuticals Q2 2026 Results: OPEX guidance cut 40% to $375 million scanx.trade
Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships. pluang.com
Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships.
AI-driven drug discovery platform.
Based on 6 signals across 1 source · snapshot 18 Sept 2026
Moderate risk indicators present across data sources.
Limited — treat this score as early-stage; more data needed.
Overall community sentiment for Recursion Pharmaceuticals is negative based on public signals as of 18 Sept 2026.
Limited coverage — score may shift as signals arrive.
Based on 6 signals across 1 source
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
This summary is generated from publicly available review and signal data. It is intended as an indicative overview only and should not be used as the sole basis for employment, investment, or business decisions. Signal volume and source diversity may limit representativeness.
AI summaries are generated from public signals and may not reflect the full picture.
Recursion Pharmaceuticals (RXRX) Stock Sinks As Cash Burn Dominates AI Drug Story webull.com